Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. - Test2 - elhamkhani - TriplyDB

Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.

Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.

http://www.wikidata.org/entity/Q34260622

about

PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application GSK-3 as potential target for therapeutic intervention in cancer Advances in targeting signal transduction pathways Molecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment EGFR-TKI resistance in NSCLC patients: mechanisms and strategies Activation of GABA(B) receptors inhibits protein kinase B/glycogen synthase kinase 3 signaling.Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer Lack of BRAF-V600E Mutation in Papillary Tumor of the Pineal Region.Dual inhibition of EGFR at protein and activity level via combinatorial blocking of PI4KIIα as anti-tumor strategy.Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trial Inhibition of PI3K/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2.Sann-Joong-Kuey-Jian-Tang induces autophagy in HepG2 cells via regulation of the phosphoinositide-3 kinase/Akt/mammalian target of rapamycin and p38 mitogen-activated protein kinase pathways.Systems biology network-based discovery of a small molecule activator BL-AD008 targeting AMPK/ZIPK and inducing apoptosis in cervical cancer.Chorein addiction in VPS13A overexpressing rhabdomyosarcoma cells Autophagy limits proliferation and glycolytic metabolism in acute myeloid leukemia Koschei the immortal and anti-aging drugs Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine ER stress: Autophagy induction, inhibition and selection.Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes.A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia Targeted drug discovery for pediatric leukemia.Integration of Different "-omics" Technologies Identifies Inhibition of the IGF1R-Akt-mTOR Signaling Cascade Involved in the Cytotoxic Effect of Shikonin against Leukemia Cells Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors.Combined inhibition of TGFβ and PDGF signaling attenuates radiation-induced pulmonary fibrosis Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome.Epigenetic deregulation of the anaplastic lymphoma kinase gene modulates mesenchymal characteristics of oral squamous cell carcinomas Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells Rapamycin extends life- and health span because it slows aging.Cytoplasmic localization of wild-type survivin is associated with constitutive activation of the PI3K/Akt signaling pathway and represents a favorable prognostic factor in patients with acute myeloid leukemia.Establishment and antitumor effects of dasatinib and PKI-587 in BD-138T, a patient-derived muscle invasive bladder cancer preclinical platform with concomitant EGFR amplification and PTEN deletion.MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia.Cyclic ADP-Ribose and NAADP in Vascular Regulation and Diseases.Application and interpretation of current autophagy inhibitors and activators.

P2860

Q26801538-2EB97493-DA7B-4B4D-8C36-50D5853CF525 Q27013811-7AAA359C-38FF-44AC-82D3-C0119BDA6DA0 Q27686983-E469B114-E8B3-4604-B421-D8769BD31329 Q28081657-51A71412-0557-4F32-AEC9-F7FFA687C3EE Q28394310-6D353CE1-E04A-4BDA-BDD6-AD4DEE220421 Q30458968-5AAB218C-9E13-45F0-97AA-A24ABE2A7568 Q30557008-C29D6417-CE65-4B1B-B2F9-74CB3D9789AF Q30977659-CC3894B8-05E1-41A4-A7CE-2EAF7DAB97F6 Q33632845-C5D3F3D3-8274-42E0-89F9-7A6854D1EAD2 Q33952803-8CFA9DCF-F2FE-4098-9D24-716CFEB75857 Q34103963-F2651428-5BF1-4B94-8EC0-B572C11FE5D6 Q34307356-7372F8F8-34B0-4D63-8FF3-0AE4A43B3088 Q34786480-67C0AD8E-C188-4EFC-8D04-3C207D1934A5 Q34848294-80C2DA01-F37B-48B2-B366-B4249F13F3E8 Q35071010-5BCDC248-FE8D-4870-AC82-5224E2242DFE Q35729047-F740ABE7-3D31-4D23-A804-85FDCF45A22A Q35781507-2542B4BF-D6CB-4C31-98DA-8A92E1B6C734 Q35832986-712546CE-4A16-4096-8185-183C6E4DB7AC Q36270307-F4A2DFEF-8F18-4AE4-A7BC-8FE3EC7804AF Q36292001-432BB87D-52AA-4CB3-980D-348FFF147872 Q36339232-C5A0088D-0102-4988-B0BD-CA1B396BD0C7 Q36544778-31B5594C-2D9B-4FFD-A5E5-61FA9D662E5E Q36556350-A366048B-EBF9-4564-A8AA-B196BA6E4B57 Q36777229-C609202D-131C-4B3A-B471-470907D641E4 Q36862768-EEA3091A-1EE0-44C6-9CFE-D2DA8FF73A50 Q36926098-86F5527B-0FA0-4489-8EEC-60D4B2016C79 Q36926129-C1433D65-F434-4AA5-9EAE-7AF4AD48CF15 Q36989223-759BD355-0160-44E9-9C77-C087AA1E36A5 Q36990482-3D486A36-A637-4FD9-908F-7B669A34004E Q37011768-27CEB9FB-4071-46E4-B853-DA700B97D95D Q37012626-28D3ACE0-A0C4-4E52-BCF1-3741A34FA4C4 Q37046021-3E7AF344-41BE-4D86-B38B-E0BB24AB7CAD Q37065337-EF3ABAF8-2477-4F4C-86ED-ACB90E824C3E Q37132224-E2151664-C7F9-4324-8C4D-6EB79C252516 Q37228766-0BE9B4E6-D112-4BEA-A9AE-6B283F826C1F Q37377906-0E80BDEA-C023-4690-9910-9897B031DB9D Q37588340-A6DB5A67-0FE0-4012-9865-6314B017D0FC Q37649646-7705FB34-361C-42DD-96C5-C4D1C946EA60 Q37704928-66E9E1F9-F054-493C-9FB3-7BC71156E3AA Q37729067-84B04630-63F5-4340-A864-1B8CE266508B

P2860

Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.

http://www.wikidata.org/entity/Q34260622

description

2012 nî lūn-bûn

@nan

2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Two hits are better than one: ...... for acute leukemia treatment.

@ast

Two hits are better than one: ...... for acute leukemia treatment.

@en

Two hits are better than one: ...... for acute leukemia treatment.

@nl

type

label

Two hits are better than one: ...... for acute leukemia treatment.

@ast

Two hits are better than one: ...... for acute leukemia treatment.

@en

Two hits are better than one: ...... for acute leukemia treatment.

@nl

prefLabel

Two hits are better than one: ...... for acute leukemia treatment.

@ast

Two hits are better than one: ...... for acute leukemia treatment.

@en

Two hits are better than one: ...... for acute leukemia treatment.

@nl

P1433

Q34260622-440F75B9-E4DD-4610-9175-2A726B56F07C

P1476

Q34260622-EFB22869-13D7-42C9-A997-42C8C9B043E4

P2093

Q34260622-390D7F53-D538-4C2B-B436-FD0D550E47E2

Q34260622-454BBD80-1F83-411C-9F15-282C84550114

Q34260622-4AF93A31-4635-4EFE-889D-5E6DA9C3D6CC

Q34260622-6099A8C2-4C42-4F18-AED9-551FD2788884

Q34260622-997F66E2-B48D-4ED7-8A11-919D7E6CC6D8

Q34260622-B6D172C7-91CE-4C3F-8061-6F520CA6092A

P275

Q34260622-834DC140-CCEC-4BB9-9779-24E1478F5B52

P2860

Q34260622-0043CFF9-408C-4BB2-8FBD-A59FD0FF44F9

Q34260622-00849980-539A-4AFA-B1AB-CFDD90BF1241

Q34260622-013B9F38-B8AA-4F0B-A6EF-F401A549C5B3

Q34260622-017365FF-8C32-4D40-9389-CA5918B2DA7D

Q34260622-030F4192-0C3F-4B4F-89CE-87E888BE32F0

Q34260622-07AF9AF3-6778-4493-A2F9-BB2A2F752E86

Q34260622-0B767920-D84A-42AE-80F2-F686024B51B0

Q34260622-0B9B0080-964F-43A9-A163-0AAD66FFD60F

Q34260622-0C5D7A04-F29A-43E2-8263-B394745DC88B

Q34260622-0C9491BA-ADD5-409F-9B0A-A411C3D2AEAB

P304

Q34260622-AC2498AA-8B53-4650-A229-DB17BF8A6694

P31

Q34260622-5566FF89-8DCD-4AB0-AA17-BC8CC5F76856

P356

Q34260622-4E447052-0F62-437A-BD54-9FCBB79B4AEE

P407

Q34260622-EB94482A-5B13-41C3-9BD3-D0EEA85B4EBB

P433

Q34260622-456F9E62-2D5F-4A39-8D4C-4C09B93BEC0F

P478

Q34260622-FD758859-62A3-4458-AFB1-896374BC1EA9

P50

Q34260622-1B8E0F9F-E87B-4AA3-B3CE-6B7C49E34416

Q34260622-94A123D1-8584-43A8-9AE6-369C23487F40

P5008

Q34260622-33180FD3-6002-4CC5-A41A-5151CBB02D38

P577

Q34260622-E283F0C8-718A-4A8D-9D6E-AFE135FAED31

P5875

Q34260622-75E00894-76E4-44D7-88A2-C34D9993AA64

P698

Q34260622-A53B43BA-E3BB-422C-AD62-96D605C8F4B3

P921

Q34260622-B76B2B26-C645-4E30-9060-65A4A7688409

Q34260622-BFB7DB77-4DDA-4FF1-A4C9-1EF747F2D03C

Q34260622-C4821606-4506-41AF-A24C-94A6453244EE

P932

Q34260622-F8D60779-7650-414E-909F-590F02FAFA23

P356

P1433

P1476

Two hits are better than one: ...... y for acute leukemia treatment

@en

P2093

Alberto M Martelli

http://www.w3.org/2001/XMLSchema#string

Alessandra Cappellini

http://www.w3.org/2001/XMLSchema#string

Daniela Bressanin

http://www.w3.org/2001/XMLSchema#string

Francesca Chiarini

http://www.w3.org/2001/XMLSchema#string

James A McCubrey

http://www.w3.org/2001/XMLSchema#string

Milena Fini

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.5 Unported

P2860

The Hallmarks of Cancer

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Mechanism of activation of protein kinase B by insulin and IGF-1

The CUL7 E3 ubiquitin ligase targets insulin receptor substrate 1 for ubiquitin-dependent degradation

Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia

A novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulin

Targeting mTOR for the treatment of AML. New agents and new directions

PHLiPPing the switch on Akt and protein kinase C signaling

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

P304

371-394

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.477

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Francesca Buontempo

Camilla Evangelisti

P5008

P577

2012-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224917330

http://www.w3.org/2001/XMLSchema#string

P698

22564882

http://www.w3.org/2001/XMLSchema#string

P921

mechanism of action

P932

3380573

http://www.w3.org/2001/XMLSchema#string